B7-H4 Antibody [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

B7-H4, also known as B7x and B7S1, is a 50 ‑ 80 kDa glycosylated member of the B7 family of immune co‑stimulatory proteins (1, 2). Mature mouse B7-H4 consists of a 230 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain which is followed by a hydrophobic C-terminal region (3 - 5). Within the ECD, mouse B7-H4 shares 90% and 99% aa sequence identity with human and rat B7-H4, respectively. It shares 21% ‑ 29% aa sequence identity with mouse B7-1, B7-2, B7-H1, B7-H2, B7‑H3, and PD-L2. B7-H4 is expressed on the surface of activated lymphocytes, macrophages, monocytes, dendritic cells, epithelial cells, and bone marrow-derived mesenchymal stem cells (4 - 8). Its binding to activated T cells dampens T cell responses and induces cell cycle arrest in the T cell (3 - 5). Reverse signaling can induce either cell cycle arrest or apoptosis in the B7-H4 expressing cell (9, 10). B7-H4 is up‑regulated in several carcinomas in correlation with tumor progression and metastasis (2, 7, 11, 12). A soluble form of B7-H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status (13 - 15). Soluble B7-H4 functions as a decoy molecule that blocks the inhibitory influence of B7-H4 on immune activation (15). Despite evidence for the involvement of B7-H4 in immune regulation, mice deficient in its expression do not show significant immune deficiencies, suggesting compensation by other molecules in vivo (16).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 1 application: IHC.

Showing Publications 1 - 3 of 3.

Publications using AF2154	Applications	Species
HL MacGregor, PS Ohashi Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target Clin. Cancer Res, 2017-03-21;0(0):. 2017-03-21 [PMID: 28325750] (IHC)	IHC
Radichev I, Maneva-Radicheva L, Amatya C, Salehi M, Parker C, Ellefson J, Burn P, Savinov A Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes. J Immunol, 2016-01-15;196(4):1495-506. 2016-01-15 [PMID: 26773144] (IHC, Mouse)	IHC	Mouse
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. U.S.A., 2007-11-27;104(49):19458-63. 2007-11-27 [PMID: 18042703] (IHC, Human)	IHC	Human

Array AF2154

• B7-H4 Antibodies
• B7-H4 Lysate
• B7-H4 Protein
• B7-H4 ELISA
• B7-H4 Proteins and Enzymes